Home Antibody All anti-CD82 antibodies
Also for CD82 (NM_001024844)
|KAI1 antibody was raised against a 15 amino acid peptide from near the carboxy terminus of human KAI1.|
|Human, Mouse, Rat
||0.5~1.0 mg/ml (Lot Dependent)
||WB: 0.5 - 1 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column (Protein A or G Sepharose)
|Homo sapiens CD82 molecule (CD82), transcript variant 2|
|4F9; C33; GR15; IA4; KAI1; R2; SAR2; ST6; TSPAN27|
|KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.|
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of KAI1 in A549 cell lysate with KAI1 antibody at (A) 0.5 and (B) 1 ug/ml.
Immunohistochemistry of KAI1 in human colon tissue with KAI1 antibody at 2.5 ug/ml.